Raj Goyal
Ophthalmology · Bedford Park, ILNPI 1699768721
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,361 of the $5,456 with a category attached, or 79.9%. 27 manufacturers reported payments, led by AbbVie at 30.9% of the total.
Across 129 payments — averaging $42.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Sight Sciences, Inc.$756
- Alcon$514
- Abbott$447
- Bausch & Lomb Americas Inc.$266
- Johnson & Johnson Surgical Vision, Inc.$211
- plus $2K from 21 others
Across 85 payments — averaging $1623.42 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$105K
- Glaukos Corporation$33K
What the payments were for
- Consulting fees$1,07520%
- Food & beverage$4,36180%
- Gifts$190%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 37 | $1,684 |
| Sight Sciences, Inc. | 17 | $756 |
| Alcon | 14 | $514 |
| Abbott | 6 | $447 |
| Bausch & Lomb Americas Inc. | 6 | $266 |
| Johnson & Johnson Surgical Vision, Inc. | 5 | $211 |
| Aerie Pharmaceuticals, Inc. | 6 | $211 |
| Johnson & Johnson Vision Care, Inc. | 2 | $183 |
| Novartis | 6 | $171 |
| Mallinckrodt Hospital Products Inc. | 2 | $162 |
| Carl Zeiss Meditec USA, Inc. | 1 | $148 |
| NEW World Medical,inc. | 3 | $95 |
| Glaukos Corporation | 3 | $88 |
| Nova Eye, Inc. | 1 | $64 |
| Thea Pharma Inc. | 3 | $61 |
| Ocular Therapeutix, Inc. | 2 | $59 |
| Sun Pharmaceutical Industries Inc. | 3 | $53 |
| Ivantis, Inc | 2 | $52 |
| Tearlab Corp | 2 | $42 |
| Carl Zeiss Meditec, Inc. | 1 | $36 |
| Beaver-visitec International, Inc. | 1 | $31 |
| Biotissue Holdings Inc. | 1 | $24 |
| Shire North American Group Inc | 1 | $22 |
| Mallinckrodt Enterprises LLC | 1 | $22 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Dompe US, Inc. | 1 | $19 |
| Optos, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,456 in reported general payments places this provider in the 80th percentile of 773 ophthalmology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 74 | $60,475 |
| LumiganBimatoprost | 52 | $27,961 |
| CombiganBrimonidine Tartrate/Timolol | 67 | $26,776 |
| Prednisolone Acetate | 327 | $12,666 |
| Latanoprost | 1,266 | $12,468 |
| Cyclosporine | 24 | $12,214 |
| Ketorolac Tromethamine | 357 | $7,447 |
| ErythromycinErythromycin Base | 659 | $6,256 |
| Brinzolamide | 23 | $4,971 |
| Travoprost | 30 | $4,842 |
| RocklatanNetarsudil Mesylat/Latanoprost | 13 | $4,343 |
| Timolol Maleate | 226 | $4,338 |
| Dorzolamide Hcl | 173 | $3,507 |
| Brimonidine Tartrate | 205 | $3,493 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 20 | $3,266 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $1,684 | $115,212193 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $211 | $4,34313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 773 ophthalmology providers in Illinois.
Other ophthalmology in Bedford Park
- Seenu HariprasadChicago$2.3M
- Lisa NijmSpringfield$1.7M
- Kathleen MornoNorth Riverside$1.2M
- Veeral ShethOak Forest$716K
- James KatzDes Plaines$642K
- Mitchell JacksonLake Villa$584K
- David LubeckHomewood$575K
- Parag MajmudarHighland Park$451K
- Daniel OwensLombard$343K
- Yannek LeidermanChicago$312K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.